美国电子药物输送设备市场规模、份额、趋势分析报告：产品、应用、细分市场预测，2025-2030

美国电子药物传输设备市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，美国电子药物输送设备市场规模预计到2030年将达到371亿美元，预测期间的复合年增长率为7.5%。

随着糖尿病、癌症相关疼痛、神经病变疼痛等慢性疾病的治疗需求日益增长，以及避孕需求的增加，电子给药装置 (EDDD) 产业应运而生。这些装置提供了一种可控的给药方法，更方便、疼痛更少，并降低了副作用的风险。 EDDD 可确保药物浓度维持在特定范围内（称为治疗窗），以达到最佳疗效。美国癌症研究所预测，2024 年美国将新增约 2,001,140 例癌症病例。其中，乳癌仍然是女性最常见的癌症类型。

预计到2024年，美国将有2,680万名气喘患者，其中包括450万名儿童，每年将导致数百万次急诊就诊和数百亿美元的医疗费用。此外，约有1,170万成年人（占4.6%）将被诊断出患有慢性阻塞性肺病）。

患者越来越倾向于在家中管理自身健康状况，因此对能够安全、有效、便捷地进行居家治疗的药物输送设备的需求也随之增加。胰岛素帮浦、自动注射器、穿戴式输液帮浦和预填充式注射器等设备已成为家庭医疗保健的必备工具，因为它们使患者能够在极少的辅助下自行用药，从而提供便利和自主性。

美国电子药物输送市场亮点

• 根据产品，植入式药物输送装置 (IDDD) 部门将主导电子药物输送装置产业，占据 2024 年 33.0% 的最大收入份额。
• 这些设备可以每日或每月输送药物，减少了频繁服药和检查的需要，非常适合忙碌人士。
• 预计智慧定量吸入器 (SMDI) 领域在预测期内将以 11.0% 的最快复合年增长率成长。
• 按应用划分，糖尿病领域在 2024 年占据电子药物传输设备产业的最大收益占有率。
• 预计预测期内肿瘤学领域将以最高的复合年增长率成长。
• 癌症患者数量的增加将推动这一增长，因为这些设备为传统注射提供了更好的替代方案，并生物有效性，使治疗剂能够直接精确地瞄准癌症组织。
• 2025年4月，雅培推出了其Proclaim DRG神经刺激系统的下一代输送系统，预计将简化下肢CRPS 1型和CRPS 2型患者的系统植入程序。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国电子药物传输设备市场变数、趋势与范围

• 市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 商业环境分析
  • 产业分析-波特五力分析
  • PESTLE分析

第四章美国电子药物输送设备市场：按产品分類的业务分析

• 2024 年及 2030 年各产品市场占有率
• 产品细分细分仪表板
• 市场规模、预测与趋势分析（按产品，2018-2030 年）
• 智慧型输液帮浦（输液系统）
• 智慧定量吸入器（吸入装置）
• 植入式药物传输装置
• 智慧经皮吸收贴片（经皮给药系统）
• 其他的

第五章美国电子药物输送设备市场：按应用进行的业务分析

• 2024 年及 2030 年各应用领域的市场占有率
• 应用程式细分仪表板
• 按应用分類的市场规模、预测和趋势分析（2018-2030 年）
• 糖尿病
• 呼吸装置
• 肿瘤学
• 心臟病学
• 其他的

第六章 竞争态势

• 参与者概览
• 企业市场分析
• 公司分类
• 战略地图
• 公司简介/上市公司
  • Medtronic
  • BD
  • Insulet Corporation
  • Tandem Diabetes Care, Inc.
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Johnson &Johnson Services, Inc.
  • United Therapeutics Corporation
  • Abbott
  • AstraZeneca

U.S. Electronic Drug Delivery Devices Market Growth & Trends:

The U.S. electronic drug delivery devices market size is anticipated to reach USD 37.1 billion by 2030, growing at a CAGR of 7.5% during the forecast period, according to a new report by Grand View Research, Inc. The growing demand for managing chronic conditions like diabetes, cancer-related pain, neuropathic pain, and contraceptive needs has contributed to the rise of the Electronic Drug Delivery Devices (EDDD) industry. These devices provide a controlled method of drug administration that is both more convenient and less painful, while also reducing the risk of side effects. They help ensure that drug levels remain within a specific range, known as the therapeutic window, for optimal effectiveness. The National Cancer Institute forecasts that around 2,001,140 new cancer cases will be diagnosed in the U.S. in 2024. Among these, breast cancer remains the most frequently diagnosed type of cancer in women.

In 2024, an estimated 26.8 million Americans were affected by asthma, including 4.5 million children. This contributes to millions of emergency department visits annually, resulting in tens of billions of dollars in healthcare expenses. In addition, approximately 11.7 million people, or 4.6% of adults, have been diagnosed with chronic obstructive pulmonary disease (COPD).

Patients increasingly prefer managing their health conditions at home, so there is a growing demand for drug delivery devices that enable safe, effective, and easy at-home treatments. Devices such as insulin pumps, auto-injectors, wearable infusion pumps, and pre-filled syringes are becoming indispensable tools in home healthcare because they allow patients to self-administer medications with minimal assistance, offering convenience and autonomy.

U.S. Electronic Drug Delivery Devices Market Highlights

• Based on product, the Implantable Drug Delivery Devices (IDDD) segment dominated the electronic drug delivery devices industry, accounting for the largest revenue share of 33.0% in 2024.
• These devices enable daily and monthly drug delivery, reducing the need for frequent dosing and checkups, making them ideal for busy individuals.
• The Smart Metered Dose Inhalers (SMDIs) segment is expected to grow at the fastest CAGR of 11.0% over the forecast period.
• Based on application, the diabetes segment led the electronic drug delivery devices industry with the largest revenue share in 2024.
• The oncology segment is estimated to grow at the largest CAGR over the forecast period.
• The rising number of cancer cases fuels the growth as these devices offer a superior alternative to traditional injections, revolutionizing drug delivery by effectively improving the bioavailability and enabling precise targeting of therapeutic agents directly to cancerous tissues.
• In April 2025, Abbott introduced a next-generation delivery system for its Proclaim DRG neurostimulation system. The system is expected to streamline the procedure for implanting a system in patients suffering from CRPS Type 1 and CRPS Type 2 of the lower extremities.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Electronic Drug Delivery Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Electronic Product Delivery Devices Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Smart Infusion Pumps (Infusion Systems)
  • 4.4.1. Smart Infusion Pumps (Infusion Systems) Market, 2018 - 2030 (USD Million)
  • 4.4.2. Non-Biologic Smart Infusion Systems
    • 4.4.2.1. Non-Biologic Smart Infusion Systems Market, 2018 - 2030 (USD Million)
  • 4.4.3. Biologic Smart Infusion Systems
    • 4.4.3.1. Biologic Smart Infusion Systems Market, 2018 - 2030 (USD Million)
    • 4.4.3.2. Smart Infusion Insulin Pumps
      • 4.4.3.2.1. Smart Infusion Insulin Pumps Market, 2018 - 2030 (USD Million)
    • 4.4.3.3. Other
      • 4.4.3.3.1. Other Market, 2018 - 2030 (USD Million)
• 4.5. Smart Metered Dose Inhalers (Inhalation Devices)
  • 4.5.1. Smart Metered Dose Inhalers (Inhalation Devices) Market, 2018 - 2030 (USD Million)
• 4.6. Implantable Drug Delivery Devices
  • 4.6.1. Implantable Drug Delivery Devices Market, 2018 - 2030 (USD Million)
  • 4.6.2. Biologic Implantable Drug Delivery Devices
    • 4.6.2.1. Biologic Implantable Drug Delivery Devices Market, 2018 - 2030 (USD Million)
  • 4.6.3. Non-Biologic Implantable Drug Delivery Devices
    • 4.6.3.1. Non-Biologic Implantable Drug Delivery Devices Market, 2018 - 2030 (USD Million)
• 4.7. Smart Transdermal Patches (Transdermal Delivery Systems)
  • 4.7.1. Smart Transdermal Patches (Transdermal Delivery Systems) Market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Electronic Drug Delivery Devices Market: Application Business Analysis

• 5.1. Application Market Share, 2024 & 2030
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Diabetes
  • 5.4.1. Electronic Drug Delivery Devices Market, for Diabetes, 2018 - 2030 (USD Million)
• 5.5. Respiratory Devices
  • 5.5.1. Electronic Drug Delivery Devices Market, for Respiratory Devices, 2018 - 2030 (USD Million)
• 5.6. Oncology
  • 5.6.1. Electronic Drug Delivery Devices Market, for Oncology, 2018 - 2030 (USD Million)
• 5.7. Cardiology
  • 5.7.1. Electronic Drug Delivery Devices Market, for Cardiology, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Electronic Drug Delivery Devices Market, for Others, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Medtronic
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. BD
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Product Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. Insulet Corporation
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Product Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. Tandem Diabetes Care, Inc.
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Product Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. Eli Lilly and Company
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Product Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. Novo Nordisk A/S
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Product Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. Johnson & Johnson Services, Inc.
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Product Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. United Therapeutics Corporation
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Product Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. Abbott
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Product Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. AstraZeneca
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Product Benchmarking
    • 6.5.10.4. Strategic Initiatives

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. U.S. electronic drug delivery devices market, by product, 2018 - 2030 (USD Million)
• Table 4. U.S. electronic drug delivery devices market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 U.S. electronic drug delivery devices market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Product outlook (USD Million)
• Fig. 9 Application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 U.S. electronic drug delivery devices market dynamics
• Fig. 12 U.S. electronic drug delivery devices market: Porter's five forces analysis
• Fig. 13 U.S. electronic drug delivery devices market: Pestle analysis
• Fig. 14 U.S. electronic drug delivery devices market: Product segment dashboard
• Fig. 15 U.S. electronic drug delivery devices market: Product market share analysis, 2024 & 2030
• Fig. 16 Smart infusion pumps (infusion systems) market, 2018 - 2030 (USD Million)
• Fig. 17 Non-biologic smart infusion systems market, 2018 - 2030 (USD Million)
• Fig. 18 Biologic Smart Infusion Systems market, 2018 - 2030 (USD Million)
• Fig. 19 Smart Infusion Insulin Pumps market, 2018 - 2030 (USD Million)
• Fig. 20 Others market, 2018 - 2030 (USD Million)
• Fig. 21 Smart metered dose inhalers (inhalation devices) market, 2018 - 2030 (USD Million)
• Fig. 22 Implantable Drug Delivery Devices market, 2018 - 2030 (USD Million)
• Fig. 23 Biologic implantable drug delivery devices market, 2018 - 2030 (USD Million)
• Fig. 24 Non-Biologic Implantable Drug Delivery Devices market, 2018 - 2030 (USD Million)
• Fig. 25 Smart transdermal patches (transdermal delivery systems) market, 2018 - 2030 (USD Million)
• Fig. 26 Others market, 2018 - 2030 (USD Million)
• Fig. 27 U.S. electronic drug delivery devices market: Application segment dashboard
• Fig. 28 U.S. electronic drug delivery devices market: Application market share analysis, 2024 & 2030
• Fig. 29 Electronic drug delivery devices market, for diabetes, 2018 - 2030 (USD Million)
• Fig. 30 Electronic drug delivery devices market, for respiratory devices, 2018 - 2030 (USD Million)
• Fig. 31 Electronic drug delivery devices market, for oncology, 2018 - 2030 (USD Million)
• Fig. 32 Electronic drug delivery devices market, for cardiology, 2018 - 2030 (USD Million)
• Fig. 33 Electronic drug delivery devices market, for others, 2018 - 2030 (USD Million)
• Fig. 34 Company categorization
• Fig. 35 Company market position analysis
• Fig. 36 Strategic framework